Key Takeaways
Novo Nordisk shares crashed more than 9% following ZEUS cardiovascular trial failure.
The trial demonstrated reduced inflammation markers but failed to prevent major heart events.
Ziltivekimab achieved a hazard ratio of 0.99 compared to placebo in the phase 3 study.
Treatment group experienced elevated serious infection rates while total mortality remained unchanged.
HERMES and ARTEMIS trials proceed with anticipated data releases in early 2027.
Shares of Novo Nordisk tumbled 9.18% to reach $46.85 following disappointing results from its ZEUS cardiovascular trial, which failed to demonstrate a reduction in major heart-related events. This clinical setback undermined investor confidence in ziltivekimab despite the drug showing clear biological effectiveness against inflammation associated with heart disease and kidney dysfunction. Nevertheless, the company emphasized that this outcome would not impact its previously announced adjusted operating profit projections for fiscal year 2026.
ZEUS Study Fails to Achieve Primary Cardiovascular Endpoint
Novo Nordisk enrolled over 6,300 participants with existing cardiovascular disease, kidney complications, and ongoing systemic inflammation in its phase 3 trial. The double-blind, placebo-controlled study evaluated a monthly 15-milligram dose of ziltivekimab administered throughout the investigation period. The primary efficacy measure tracked a composite endpoint including cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke events.
Treatment with ziltivekimab successfully decreased free interleukin-6 levels and high-sensitivity C-reactive protein concentrations, demonstrating robust target engagement throughout the patient population. Despite these favorable biological responses, the drug failed to significantly reduce major adverse cardiovascular events compared with placebo during the observation period. The study recorded a hazard ratio of 0.99, accompanied by a 95% confidence interval spanning 0.88 to 1.11.
The frequency of overall adverse events and serious adverse events remained comparable between treatment and placebo arms. However, participants receiving ziltivekimab experienced a higher incidence of serious infections, consistent with anticipated consequences of IL-6 pathway blockade. Importantly, Novo Nordisk observed no significant variation in all-cause mortality between the two study cohorts throughout the monitoring period.
Company Maintains Commitment to Additional Cardiovascular Studies
Novo Nordisk announced it will advance two additional cardiovascular outcome trials evaluating ziltivekimab notwithstanding the negative ZEUS findings. The HERMES trial examines the drug’s effectiveness in individuals with heart failure who remain at elevated cardiovascular risk. Concurrently, ARTEMIS investigates ziltivekimab in patients following acute myocardial infarction who face increased risk of subsequent cardiovascular complications.
Top-line data from both investigations are expected during the first half of 2027, based on the company’s present development schedule. These trials target distinct cardiovascular patient populations, potentially yielding results that diverge substantially from ZEUS trial outcomes. Consequently, Novo Nordisk maintains access to critical clinical data points before determining the long-term strategic direction for this experimental therapy.
The ZEUS outcome will necessitate a non-cash impairment charge recorded in the third quarter of fiscal 2026. Despite this financial impact, Novo Nordisk confirmed the charge would not modify its existing adjusted operating profit guidance for the year. The sharp stock decline reflects investor apprehension regarding pipeline valuation following the failure of this major cardiovascular trial to meet its primary efficacy goal.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
